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See Article, pages 135–142The liver is the key metabolic organ in the human body, which
contributes to immune responses against viruses, toxins, bacte-
ria, and parasites. The antigen-rich blood from the gastrointesti-
nal tract ﬂows through a network of liver sinusoids and is
scanned by liver antigen-presenting cells [1]. This unique anat-
omy of the liver may facilitate direct or indirect priming of lym-
phocytes, modulate the immune response to hepatotropic
pathogens and contribute to the immune tolerogenic properties
of this organ. The liver speciﬁc immune response depends on a
specialized intrahepatic cell composition, non-parenchymal cells
(NPC), which consists of endothelial cells (liver sinusoidal endo-
thelial cells), Kupffer cells, biliary epithelial cells, hepatic stellate
cells, liver associated lymphocytes, and dendritic cells (DCs) [1,2].
DCs develop from bone-marrow progenitor cells, are hetero-
geneous and consist of several subtypes with a high diversity in
phenotype and functional properties [3]. To date ﬁve major DC
subsets are characterised in lymphoid and non-lymphoid tissue:
(i) Langerhans cell (LC), (ii) CD11b+-like DCs, (iii) CD8a+-like DCs,
(iv) plasmacytoid DC (pDC), and (v) monocyte-derived inﬂamma-
tory-DC [4,5]. The knowledge gained by employing the novel
genomic proﬁling methods revealed that mouse DCs are not rep-
resentative of human DCs [6] and DCs of both species are differ-
ent in phenotype and function. For example, the mouse DC
surface marker CD8a, which potently cross-present exogenous
antigens and which efﬁciently activate CD8+ T cells, is not
expressed in human DCs. The study of phenotype and function
of human liver DCs is therefore urgently required, not only to
understand the pathophysiology of liver disease, but in particular
to exploit their therapeutic potential, e.g., for cellular therapy.
DCs are lacking the lineage markers and constitutively
express MHC class II. In human blood circulation, there are two
CD8a+-like DC subsets, which could be subdivided by the expres-
sion of CD1c (BDCA1) or CD141 (BDCA3) [7]. Recently, CD141+
DCs were discovered in human skin, lung, and liver [8]. Moreover,
CD141+ DCs were detected in the lung of humanized mice that
were reconstituted with human hematopoietic progenitors [9].
Studies of non-lymphoid resident DCs in human organs are very
restricted due to the availability of the tissues and are limited toJournal of Hepatology 20
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Open access under CC BY-NC-ND license.organs from patients subjected to surgery for an underlying dis-
ease. Hence, it is possible that the disease affects the frequency of
DCs and their function. So far, there is only the possibility to ana-
lyze hepatic DCs phenotype and function from explanted tissues.
Acute or chronic liver failure is often associated with pro-inﬂam-
matory immune responses. However, for usage of DCs in cellular
therapy, studying the steady-state frequency, phenotype, and
function of DCs originated from healthy donors are important.
Cytokines secreted from DC subsets are critical for modulating
immune responses both, in a tolerogenic way by expressing IL-
10 or in a pro-inﬂammatory manner by producing, e.g., TNF-a,
IL-6, and IL-1. Additionally, DCs have been reported to secrete
IFN-k in response to viral infection [10]. IFN-k is a type III inter-
feron, which has been reported to be very crucial in the anti-viral
immune response towards hepatotropic viruses [11].
Up to now, human DCs were obtained from digested peritu-
moral non-lymphoid tissues, e.g., liver and lung [8], where the
tumor milieu as well as the isolation method could have affected
DC phenotype and function. However, in the current issue of the
Journal of Hepatology, Kelly and colleagues describe a very ele-
gant approach to isolate hepatic mononuclear cells (HMNCs)
from human healthy adults. Hepatic DCs were isolated during
liver transplantation from perfusates of explanted livers of
healthy allograft donors without tissue destruction as well as
from diseased recipients transplanted for, e.g., hepatocellular car-
cinoma (HCC) due to HCV infection, HCV infection without HCC,
alcoholic liver disease, non-alcoholic steatohepatitis (NASH),
and polycystic liver disease. In their study, Kelly and colleagues
examined the healthy hepatic DCs in comparison to human blood
DCs and the DCs isolated from diseased livers for (i) expression of
several surface molecules, (ii) secretion of cytokines in response
to poly(I:C) stimulation and (iii) the ability to activate T cells in
allogeneic mixed lymphocyte reactions (MLR).
Kelly and colleagues demonstrated that the frequencies of res-
ident hepatic DCs are different from those of circulating DCs.
Almost half of blood and liver perfusate DC populations are
CD11c+ myeloid (m)DCs, however, the ratios of the two CD11c+
subsets, CD1c+ and CD141+, are inverse in blood vs. liver. While
the CD1c+ DCs are the main subset in the blood, it is CD141+
DCs, which are the main population within the hepatic DCs.
Intrahepatic DCs are predominantly immature cells [12].
Under steady state conditions they are tolerogenic and able to
inhibit cell proliferation of liver inﬁltrating lymphocytes. Kelly
and colleagues analyzed the CD141+ DC subset for expression14 vol. 60 j 9–11
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Fig. 1. Possible role of CD141+ DC subsets in the immune response. Upon viral
infection CD141+CLEC9A+ DCs become activated and release IFNlambda (IFN-k).
Subsequently, conventional CD8+ T cells are recruited to the liver to clear the
infection. On the other hand, ILT3+ILT4+CD141+ DCs become activated with
several stimuli and might induce the regulation of the immune response, e.g., by
induction of regulatory T cells (Tregs). This might promote the healing and
regeneration process in the liver.
Editorialof the tolerogenic markers ILT3 and ILT4 [13] and the C-type lec-
tin receptor CLEC9A that mediates antigen uptake and cross-pre-
sentation by human DCs [14]. Most of hepatic CD11c+ DCs (>90%)
are ILT3- and ILT4-positiv. There is only a small CD11c+CD141+
CLEC9A+ DC subset (<1%) and of this population roughly 50% of
the CD141+ DCs were ILT3+ and ILT4+, probably representing a
tolerogenic cell population. The authors also detected a subset
of CD141+ DCs with high levels of CLEC9A expression, which
are ILT3- and ILT4-negative. These CD141+CLEC9A+ILT3ILT4
DCs are similar to mouse CD8a+-like DC cells with high capacity
for cross presentation [8]. The authors demonstrated that
CD141+ DCs activate T cells with a higher proliferation rate in
comparison to CD141 DCs and induce an expansion of Th1
and Th17 cells as well as of IFNc producing CD8+ T cells. More-
over, CD141+ DCs released high amounts of IFN-k in response
to poly(I:C), which mimics viral signals and therefore indicates
a possible role for TLR3 mediated immune responses against viral
infection by these cells. Interestingly, only a very low frequency
of CD141+ DCs was detected in diseased livers, irrespective of
the underlying liver disease, however, with an increased poten-
tial for IFN-k production upon poly(I:C) stimulation compared
to CD141+ DCs from healthy livers.
The method Kelly and colleagues performed to isolate HMNCs
from healthy donor livers during orthotopic transplantation
seems to be gentle and offers the unique opportunity to charac-
terize DCs and lymphocyte composition of the liver under
steady-state conditions. Moreover, DCs could be puriﬁed from
this population for cellular therapy. During transplantation, Uni-
versity of Wisconsin (UW) solution stored livers were perfused
with normal saline. This perfusate as well as the UW solution
were used for the cell isolation procedure. There seems to be
minimal mechanical stress often observed during crushing of
solid tissue as well as a lack of surface molecule disruption by
digestive compounds. Therefore, this paper represents a potential
major step forward in the study of human liver DCs by
highlighting a novel gentle isolation procedure of human DCs,10 Journal of Hepatology 2which can be carried out during transplantation surgery without
destruction of the transplanted organ and with the opportunity
to expand these cells for cellular therapy.
However, for a better examination of human hepatic DC
subsets, development of in vitro differentiation protocols is nec-
essary. It is important for the development of cellular therapy
that the inﬂuence of drugs or other compounds can be assayed
in these cells in vitro. In the context of cellular immune therapy
CD141+CLEC9A+ DCs are a potential cell population that could
be employed in clinical applications. Further characterization
of this DC subset is necessary to clarify immune regulation of
the cells in different pathological circumstances. IFN-k release
by these cells is quite encouraging to use the cells for cellular
therapy in chronic viral infection, where boosting of an anti-
viral immune response is required. Since the frequency of these
cells is greatly reduced in diseased livers, also during viral hep-
atitis, it would be a reasonable approach to increase the num-
ber of the CD141+CLEC9A+ DC subset in the liver, e.g., by
adoptive transfer, and thus potentiate cross-presentation of
viral antigens to CD8+ T cells, thereby accelerating viral
clearance. On the other hand, increase in the frequency of
ILT3+ILT4+CD141+ DCs, which are tolerogenic, could be beneﬁ-
cial in the circumstance that the suppression of inﬂammation
is desired (Fig. 1).
In conclusion the study presented by Kelly and colleagues
gives important information about a new and elegant method
to isolate viable cells from human liver tissue. This study also
provides very important information about the DC composition
in healthy human liver and the changes that occur in DC subsets
in diseased liver.Conﬂict of interest
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